Clinically significant prostate cancer occurred in 3.6% of MSH2 carriers versus 0% in non-carriers, leading the study authors to recommend targeted PSA screening in men with MSH2 and MSH6 variants [153]. This evidence concerns the gene MSH6 and prostate carcinoma.